Shares of Mast Therapeutics Inc (NYSE:MSTX) have received an average rating of “Hold” from the seven ratings firms that are presently covering the company. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $1.70.

Several equities research analysts have recently commented on the stock. S&P Equity Research boosted their target price on shares of Mast Therapeutics from $0.08 to $0.09 in a research report on Friday, October 14th. Maxim Group set a $5.00 target price on shares of Mast Therapeutics and gave the stock a “buy” rating in a research report on Monday, August 8th. Roth Capital reissued a “buy” rating and set a $2.00 target price on shares of Mast Therapeutics in a research report on Monday, August 1st. Canaccord Genuity reissued a “buy” rating and set a $3.00 target price on shares of Mast Therapeutics in a research report on Thursday, July 28th. Finally, Zacks Investment Research raised shares of Mast Therapeutics from a “sell” rating to a “buy” rating and set a $0.25 target price for the company in a research report on Friday, September 23rd.

Shares of Mast Therapeutics (NYSE:MSTX) opened at 0.0927 on Monday. Mast Therapeutics has a 52 week low of $0.07 and a 52 week high of $0.71. The company has a 50-day moving average of $0.08 and a 200 day moving average of $0.31. The firm’s market capitalization is $22.08 million.

Mast Therapeutics (NYSE:MSTX) last posted its quarterly earnings results on Tuesday, November 8th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.01. Equities research analysts anticipate that Mast Therapeutics will post ($0.19) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright & trademark law. The original version of this article can be read at https://www.thecerbatgem.com/2016/11/24/analysts-set-mast-therapeutics-inc-mstx-target-price-at-1-70.html.

Mast Therapeutics Company Profile

Mast Therapeutics, Inc is a biopharmaceutical company. The Company develops clinical-stage therapies for serious or life-threatening diseases with unmet needs. The Company focuses on developing new therapies for sickle cell disease, a chronic and genetic disorder classified as a rare, or orphan, disease in the United States of America and European Union, and for heart failure, a condition with an unmet need for treatment options.

5 Day Chart for NYSE:MSTX

Receive News & Stock Ratings for Mast Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc and related stocks with our FREE daily email newsletter.